AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
So, in addition to the general discovery of target specific molecular compounds, the availability of binders to pharmacologically important, but so-far “undruggable” target proteins opens new possibilities to develop novel drugs for diseases that could not be treated so far. In eliminating the requirement to initially assess the activity of hits it is hoped and expected that many of the high affinity binders identified will be shown to be active in independent analysis of selected hits, therefore offering an efficient method to identify high quality hits and pharmaceutical leads.
=== Conservative === There is currently no medical recommendation about how to manage an inguinal hernia condition in adults, due to the fact that, until the early 2010s, elective surgery used to be recommended. The hernia truss (or hernia belt) is intended to contain a reducible inguinal hernia within the abdomen. It is not considered to provide a cure, and if the pads are hard and intrude into the hernia aperture, they may cause scarring and enlargement of the aperture. In addition, most trusses with older designs are unable to effectively contain the hernia at all times, because their pads do not remain permanently in contact with the hernia. The more modern variety of truss is made with non-intrusive flat pads and comes with a guarantee to hold the hernia securely during all activities. They have been described by users as providing greater confidence and comfort when carrying out physically demanding tasks. However, their use is controversial, as data to determine whether they help prevent hernia complications is lacking. A truss also increases the probability of complications, which include strangulation of the hernia, atrophy of the spermatic cord, and atrophy of the fascial margins. This allows the defect to enlarge and makes subsequent repair more difficult. Their popularity is nonetheless likely to increase, as many individuals with small, painless hernias are now delaying hernia surgery due to the risk of post-herniorrhaphy pain syndrome. Elasticated pants used by athletes may also provide useful support for the smaller hernia.
=== Related drugs === Parke-Davis developed a drug called pregabalin, which is related in structure to gabapentin, as a successor to gabapentin. Another similar drug atagabalin has been unsuccessfully tried by Pfizer as a treatment for insomnia. A prodrug form (gabapentin enacarbil) was approved by the US Food and Drug Administration (FDA).
Sources: en.wikipedia.org
John D. Rockefeller Sr. first conceived the idea of the foundation in 1901. In 1906, Rockefeller's business and philanthropic advisor, Frederick Taylor Gates, encouraged him toward "permanent corporate philanthropies for the good of Mankind" so that his heirs should not "dissipate their inheritances or become intoxicated with power." In 1909 Rockefeller signed over 73,000 Standard Oil shares worth $50 million, to his son, Gates and Harold Fowler McCormick as the third inaugural trustee, in the first installment of a projected $100 million endowment. The nascent foundation applied for a federal charter in the US Senate in 1910, with at one stage Junior even secretly meeting with President William Howard Taft, through the aegis of Senator Nelson Aldrich, to hammer out concessions. However, because of the ongoing (1911) antitrust suit against Standard Oil at the time, along with deep suspicion in some quarters of undue Rockefeller influence on the spending of the endowment, the result was that Senior and Gates withdrew the bill from Congress in order to seek a state charter from New York.
== Biomedical applications == DNA origami, being made of a natural biological polymer, is well suited to the biological environment when salt concentrations allow, and offers fine control over the positioning of molecules and structures in the system. This allows DNA origami to be applicable to a number of scenarios in biomedical engineering. Current biomedical applications include drug release with 0 order mechanisms, vaccines, cell signaling, and sensing applications. DNA is folded into an octahedron and coated with a single bilayer of phospholipid, mimicking the envelope of a virus particle. The DNA nanoparticles, each at about the size of a virion, are able to remain in circulation for hours after being injected into mice. It also elicits a much lower immune response than the uncoated particles. It presents a potential use in drug delivery, reported by researchers at the Wyss Institute at Harvard University. Researchers at the Harvard University Wyss Institute reported the self-assembling and self-destructing drug delivery vessels using the DNA origami in the lab tests. The DNA nanorobot they created is an open DNA tube with a hinge on one side which can be clasped shut. The drug filled DNA tube is held shut by a DNA aptamer, configured to identify and seek certain diseased related protein. Once the origami nanobots get to the infected cells, the aptamers break apart and release the drug. The first disease model the researchers used was leukemia and lymphoma.
Guinness Bitter, an English-style bitter beer: 4.4% ABV. Guinness Extra Smooth, a smoother stout sold in Ghana, Cameroon and Nigeria: 5.5% ABV. Malta Guinness, a non-alcoholic beverage, produced in Nigeria and exported to the UK, East Africa, and Malaysia. Guinness Zero ABV, a non-alcoholic beverage sold in Indonesia. Guinness Mid-Strength, a low-alcohol stout test-marketed in Limerick, Ireland in March 2006 and Dublin from May 2007: 2.8% ABV. Guinness Red, brewed in exactly the same way as Guinness except that the barley is only lightly roasted so that it produces a lighter, slightly fruitier red ale; test-marketed in Britain in February 2007: 4% ABV. 250 Anniversary Stout, released in the U.S., Australia and Singapore on 24 April 2009; 5% ABV. Guinness West Indies, a Porter which imitates the 1801 variety with notes of toffee and chocolate: 6% ABV. In October 2005, Guinness announced the Brewhouse Series, a limited-edition collection of draught stouts available for roughly six months each. There were three beers in the series.
== External links == Radioactive isotope table "lists ALL radioactive nuclei with a half-life greater than 1000 years", incorporated in the list above. The NUBASE2020 evaluation of nuclear physics properties F.G. Kondev et al. 2021 Chinese Phys. C 45 030001. The PDF of this article lists the half-lives of all known radioactives nuclides.
Sources: en.wikipedia.org
all the Francoist institutions without exception, so that the reform law actually liquidated what it was intended to reform. In addition, the new attitude of the government and especially that of its president changed the political climate, overcoming the tension that had been experienced during the government of Arias Navarro. On July 31, the government approved the amnesty, one of the main demands of the anti-Francoist opposition, although "blood crimes" were excluded, so that many "Basque prisoners", alleged members of ETA, remained in jail. This coupled with the fact that demonstrations in the Basque Country and Navarre were normally banned precisely because they included the request for amnesty for "Basque prisoners" and the claim for self-government which the authorities immediately linked to ETA activity ─ which continued with the attacks ─ would explain that there the climate of tension (and political radicalization) increased while in the rest of Spain it decreased. The obstacle that most worried the government to carry out the "political reform" was not what the democratic opposition could say, but rather the Army, that was considered the ultimate guarantor of "Franco's legacy". On September 8, Adolfo Suarez met with the military leadership to convince the high command of the need for reform.
== Research and career == Okan worked as a research fellow for one year at the Cleveland Clinic, USA. He studied wound care after laser resurfacing. He participated in the clinical and research activities of the Cleveland Clinic Florida Dermatology Department, published several clinical research articles and conducted clinical research projects. His research interest has focused on psoriasis, vitiligo, rosacea, laser and dermatologic signs of systemic diseases and wound healing. In April 2015, Okan published a popular book about dermatology, "Krem-Cilt Sağlığının ABC'si" ("Cream: The ABC's of Skin Care"). The book reflects day-to-day clinical experience and direct knowledge of cutting edge advances, advising people to choose cosmetic products carefully, and to maintain proper nutrition and hydration. He particularly advises parsley, nettle, chamomile, ginseng, thyme, melon, broccoli, and carrot, as well as Vitamin A, Vitamin B3, Vitamin C, Vitamin D, Vitamin K, Vitamin H, zinc and iron. In other media, Okan has also deemed a good-quality sunscreen to be the best defense against aging. Later in 2015, he participated in 23rd World Congress of Dermatology, in Vancouver. Okan is a European Board Certified dermatologist and passed the Specialty Certificate Examination (SCE) in Dermatology in the UK.
== Biosynthesis == α-Amanitin and other amatoxins are synthesized on ribosomes and modified by several tailoring enzymes. The ribosomally synthesized peptide, called the precursor peptide, is recognized by a Prolyl Oligopeptidase B (POPB) enzyme. POPB cleaves the precursor peptide and cyclizes the remaining octapeptide. Following cyclization, the peptide is hydroxylated by P450-29 and FMO1 enzymes. The hydroxylations of isoleucine and tryptophan contribute to the high-affinity binding of α-amanitin to RNA polymerase II. Unknown enzyme machinery installs the tryptathionine bridge.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.